Lyra Therapeutics Inc (LYRA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.20 (+0.00%), Market cap $0.00B, 52-week low–high $0.09 ~ $27.58.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Infl
Financial statements, price targets, institutional (13F) holdings and related news for Lyra Therapeutics Inc are updated in real time on BlackAll Trade.
Lyra Therapeutics Inc trades at $0.20 (+0.00%). Real-time quotes and charts are available on BlackAll Trade.
Lyra Therapeutics Inc has a market cap of about $0.00B.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusit